{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:33:48Z","timestamp":1769081628956,"version":"3.49.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2003,3,1]],"date-time":"2003-03-01T00:00:00Z","timestamp":1046476800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Trends in Biotechnology"],"published-print":{"date-parts":[[2003,3]]},"DOI":"10.1016\/s0167-7799(02)00042-2","type":"journal-article","created":{"date-parts":[[2003,3,15]],"date-time":"2003-03-15T05:43:28Z","timestamp":1047707008000},"page":"117-122","source":"Crossref","is-referenced-by-count":168,"title":["Latest development in viral vectors for gene therapy"],"prefix":"10.1016","volume":"21","author":[{"given":"Kenneth","family":"Lundstrom","sequence":"first","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/S0167-7799(02)00042-2_BIB1","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1126\/science.288.5466.669","article-title":"Gene therapy of human severe combined immune deficiency (SCID)-X1 disease","volume":"288","author":"Cavazzana-Calvo","year":"2000","journal-title":"Science"},{"key":"10.1016\/S0167-7799(02)00042-2_BIB2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1089\/10430340152712719","article-title":"A pilot study of in vivo liver-directed gene transfer with an Adenoviral vector in partial ornitine transcarbamylase deficiency","volume":"13","author":"Raper","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB3","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/420116a","article-title":"Gene therapy: a tragic setback","volume":"420","author":"Check","year":"2002","journal-title":"Nature"},{"key":"10.1016\/S0167-7799(02)00042-2_BIB4","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/1467-8519.00257","article-title":"Points to consider for ethics committees in human gene therapy trials","volume":"15","author":"Dettweiler","year":"2001","journal-title":"Bioethics"},{"key":"10.1016\/S0167-7799(02)00042-2_BIB5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/S0958-1669(98)80031-1","article-title":"Adeno-associated virus expression systems for gene transfer","volume":"9","author":"Rabinowtz","year":"1998","journal-title":"Curr. Opin. Biotechnol."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB6","doi-asserted-by":"crossref","first-page":"3428","DOI":"10.1073\/pnas.050581197","article-title":"Recombinant adeno-associated virus type 2, 4, and 5 vectors: transduction of variant cell types and regions in the mammalian central nervous system","volume":"97","author":"Davidson","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB7","doi-asserted-by":"crossref","first-page":"11854","DOI":"10.1073\/pnas.182412299","article-title":"Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy","volume":"99","author":"Gao","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB8","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1006\/mthe.2002.0660","article-title":"Pharmacological regulation of protein expression from adeno-associated viral vectors in the eye","volume":"6","author":"Auricchio","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB9","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1002\/ijc.10077","article-title":"Enhancement of cisplatin-induced apoptosis by infection with adeno-associated virus type 2","volume":"97","author":"Duverger","year":"2002","journal-title":"Int. J. Cancer"},{"key":"10.1016\/S0167-7799(02)00042-2_BIB10","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0298-180","article-title":"Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity","volume":"18","author":"Schiedner","year":"1998","journal-title":"Nat. Genet."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB11","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1006\/mthe.2000.0410","article-title":"A capsid-modified adenovirus vector devoid of all viral genes: assessment of transduction and toxicity in human hematopoietic cells","volume":"4","author":"Stecher","year":"2001","journal-title":"Mol. Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB12","first-page":"4273","article-title":"Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors","volume":"62","author":"Haviv","year":"2002","journal-title":"Cancer Res."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB13","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/sj.gt.3301389","article-title":"Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies","volume":"8","author":"Fisher","year":"2001","journal-title":"Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB14","doi-asserted-by":"crossref","first-page":"1887","DOI":"10.1089\/104303402760372972","article-title":"PEGylation of E1-deleted Adenovirus vectors allows significant gene expression on readministration to liver","volume":"13","author":"Croyle","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB15","doi-asserted-by":"crossref","first-page":"9314","DOI":"10.1128\/JVI.73.11.9314-9324.1999","article-title":"Integrating adenovirus-adeno-associated virus hybrid vectors devoid of all viral genes","volume":"73","author":"Lieber","year":"1999","journal-title":"J. Virol."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/1566523013349039","article-title":"Alphavirus vectors for gene therapy applications","volume":"1","author":"Lundstrom","year":"2001","journal-title":"Curr. Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB17","first-page":"28","article-title":"Alphavirus-based vaccines","volume":"4","author":"Lundstrom","year":"2002","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB18","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1038\/sj.gt.3300841","article-title":"Transfer of the murine interleukin-12 gene in vivo by a Semliki Forest virus vector induces B16 tumor regression through inhibition of tumor blood vessel formation monitored by Doppler ultrasonography","volume":"6","author":"Asselin-Paturel","year":"1999","journal-title":"Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB19","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/sj.gt.3301263","article-title":"Inhibition of human lung carcinoma cell growth by apoptosis induction using Semliki Forest virus recombinant particles","volume":"7","author":"Murphy","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB20","doi-asserted-by":"crossref","first-page":"611","DOI":"10.3171\/jns.2002.97.3.0611","article-title":"Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12","volume":"97","author":"Yamanaka","year":"2002","journal-title":"J. Neurosurg."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB21","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1089\/10430340252809847","article-title":"Cancer immunotherapy using Sindbis virus replicon particles encoding a VP22-antigen fusion","volume":"13","author":"Cheng","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nbt0897-763","article-title":"Cell-specific targeting of Sindbis virus vectors displaying IgG-binding domains of protein A","volume":"15","author":"Ohno","year":"1997","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB23","unstructured":"Lundstrom, K. and Boulikas, T. Breakthrough in cancer therapy: encapsulation of drugs and viruses. Curr. Drug Disc. (in press)."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB24","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1128\/JVI.72.4.3307-3320.1998","article-title":"Persistence and expression of the herpes simplex virus genome in the absence of immediate-early proteins","volume":"72","author":"Samaniego","year":"1998","journal-title":"J. Virol."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB25","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1128\/JVI.68.4.2239-2252.1994","article-title":"A novel latency-active promoter is contained within the herpes simplex virus type 1 UL flanking repeats","volume":"68","author":"Goins","year":"1994","journal-title":"J. Virol."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB26","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1073\/pnas.96.6.3211","article-title":"Antihypergelsic effects of infection with a preproenkephalin-encoding herpes simplex virus","volume":"96","author":"Wilson","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB27","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/sj.gt.3300766","article-title":"Deletion of immediate early genes from herpes simplex virus reduces cytotoxicity and permits long-term gene expression in neurons","volume":"5","author":"Krisky","year":"1998","journal-title":"Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB28","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1038\/sj.gt.3301782","article-title":"HSV1716 persistence in primary human glioma cells in vitro","volume":"9","author":"Harland","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB29","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1006\/mthe.2000.0101","article-title":"Effective treatment of experimental glioblastoma by herpes simplex virus type-1 vector-mediated TNFalpha and HSV-tk gene transfer in combination with radiosurgery and ganciclovir administration","volume":"2","author":"Niranjan","year":"2000","journal-title":"Mol. Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB30","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/(SICI)1521-2254(199907\/08)1:4<280::AID-JGM45>3.0.CO;2-L","article-title":"Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle","volume":"1","author":"Akkaraju","year":"1999","journal-title":"J. Gene Med."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB31","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/sj.gt.3301054","article-title":"Genetically modified CD34+ cells as cellular vehicles for gene delivery into areas of angiogenesis in a rhesus model","volume":"7","author":"Gomez Navarro","year":"2000","journal-title":"Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB32","doi-asserted-by":"crossref","first-page":"8033","DOI":"10.1073\/pnas.90.17.8033","article-title":"Vesicular stomatitis virus G glycoprotein pseudotyped retroviral vectors: concentration to very high titer and efficient gene transfer into mammalian and nonmammalian cells","volume":"90","author":"Burns","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB33","first-page":"493","article-title":"Design of retroviral vectors and helper cells for gene therapy","volume":"52","author":"Hu","year":"2000","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB34","first-page":"2443","article-title":"Tumor growth suppression by a retroviral vector displaying scFv antibody to CEA and carrying the iNOS gene","volume":"22","author":"Khare","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB35","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1126\/science.270.5235.475","article-title":"T-lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years","volume":"270","author":"Blaese","year":"1995","journal-title":"Science"},{"key":"10.1016\/S0167-7799(02)00042-2_BIB36","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1126\/science.276.5319.1719","article-title":"HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia","volume":"276","author":"Bonini","year":"1997","journal-title":"Science"},{"key":"10.1016\/S0167-7799(02)00042-2_BIB37","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/1521-2254(200009\/10)2:5<308::AID-JGM131>3.0.CO;2-3","article-title":"Lentiviral vectors: excellent tools for experimental gene transfer and promising candidates for gene therapy","volume":"2","author":"Vigna","year":"2000","journal-title":"J. Gene Med."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB38","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/83324","article-title":"Viral vectors for gene therapy: the art of turning infectious agents into vehicles for therapeutics","volume":"7","author":"Kay","year":"2001","journal-title":"Nat. Med."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB39","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1089\/10430340252769770","article-title":"Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors","volume":"13","author":"Follenzi","year":"2002","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB40","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/sj.gt.3301708","article-title":"Gene transduction efficiency in cells of different species by HIV and EIAV","volume":"9","author":"Ikeda","year":"2002","journal-title":"Gene Ther."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB41","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1073\/pnas.032652399","article-title":"Stable suppression of gene expression by RNAi in mammalian cells","volume":"99","author":"Paddison","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB42","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/nrg908","article-title":"Gene silencing in mammalis by small interfering RNAs","volume":"3","author":"McManus","year":"2002","journal-title":"Nat. Rev."},{"key":"10.1016\/S0167-7799(02)00042-2_BIB43","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/nbt739","article-title":"siRNA-mediated gene silencing in vitro and in vivo","volume":"20","author":"Xia","year":"2002","journal-title":"Nat. Biotechnol."}],"container-title":["Trends in Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779902000422?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167779902000422?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,3,12]],"date-time":"2020-03-12T02:14:12Z","timestamp":1583979252000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167779902000422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,3]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2003,3]]}},"alternative-id":["S0167779902000422"],"URL":"https:\/\/doi.org\/10.1016\/s0167-7799(02)00042-2","relation":{},"ISSN":["0167-7799"],"issn-type":[{"value":"0167-7799","type":"print"}],"subject":[],"published":{"date-parts":[[2003,3]]}}}